Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
18th October 2024 Uncategorised 0 Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
fkansteiner
Fri, 10/18/2024 – 15:21
More: Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
Source: fierce
